Cargando…

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives

BACKGROUND: Renal masses detection is continually increasing worldwide, with Renal Cell Carcinoma (RCC) accounting for approximately 90% of all renal cancers and remaining one of the most aggressive urological malignancies. Despite improvements in cancer management, accurate diagnosis and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urso, Luca, Castello, Angelo, Rocca, Giovanni Christian, Lancia, Federica, Panareo, Stefano, Cittanti, Corrado, Uccelli, Licia, Florimonte, Luigia, Castellani, Massimo, Ippolito, Carmelo, Frassoldati, Antonio, Bartolomei, Mirco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Review – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114025/ https://www.ncbi.nlm.nih.gov/pubmed/35217902 http://dx.doi.org/10.1007/s00432-022-03958-7

Ejemplares similares

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

The Role of [(68)Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review
por: Caracciolo, Matteo, et al.
Publicado: (2022)

Lutathera(®) Orphans: State of the Art and Future Application of Radioligand Therapy with (177)Lu-DOTATATE
por: Urso, Luca, et al.
Publicado: (2023)

Relevance of Volumetric Parameters Applied to [(68)Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
por: Urso, Luca, et al.
Publicado: (2023)

The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review
por: Urso, Luca, et al.
Publicado: (2023)

18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?
por: Urso, Luca, et al.
Publicado: (2022)

The Role of [(18)F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach
por: Urso, Luca, et al.
Publicado: (2022)

PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review
por: Urso, Luca, et al.
Publicado: (2022)

Comparison of MRI vs. [(18)F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives
por: Caracciolo, Matteo, et al.
Publicado: (2023)

Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review
por: Urso, Luca, et al.
Publicado: (2022)

Glucose Metabolism Modification Induced by Radioligand Therapy with [(177)Lu]Lu/[(90)Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
por: Urso, Luca, et al.
Publicado: (2022)

Clinical-Diagnostic Relevance of Breast “Incidentaloma” Detected During 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography: Correlation with Radiological Imaging and Histopathology
por: Panareo, Stefano, et al.
Publicado: (2021)

Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report
por: Nieri, Alberto, et al.
Publicado: (2023)

(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans
por: Uccelli, Licia, et al.
Publicado: (2021)

The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria
por: Castello, Angelo, et al.
Publicado: (2022)

Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report
por: Panareo, Stefano, et al.
Publicado: (2020)

The Value of Semiquantitative Parameters Derived from (18)F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer
por: Urso, Luca, et al.
Publicado: (2022)

Role of 18F-FDG PET/CT in evaluating lymph node status in patients with head and neck squamous cell carcinoma
por: Bianchini, Chiara, et al.
Publicado: (2023)

Rhenium Radioisotopes for Medicine, a Focus on Production and Applications
por: Uccelli, Licia, et al.
Publicado: (2022)

Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008–2018)
por: Uccelli, Licia, et al.
Publicado: (2019)

Correction: Uccelli, L., et al. Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008–2018). Molecules 2019, 24, 640
por: Uccelli, Licia, et al.
Publicado: (2019)

Incidental Findings of Acute Myeloid Leukemia in Sjögren's Syndrome Detected by Nuclear Medicine Techniques
por: Castello, Angelo, et al.
Publicado: (2022)

Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000–2022)
por: Riondato, Mattia, et al.
Publicado: (2023)

Technetium-99m Radiopharmaceuticals for Ideal Myocardial Perfusion Imaging: Lost and Found Opportunities
por: Boschi, Alessandra, et al.
Publicado: (2022)

Influence of Storage Temperature on Radiochemical Purity of (99m)Tc-Radiopharmaceuticals
por: Uccelli, Licia, et al.
Publicado: (2018)

Dosimetry of (177)Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol
por: Sarnelli, Anna, et al.
Publicado: (2019)

Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications
por: Pastorino, Sara, et al.
Publicado: (2020)

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023)

Validation of [Formula: see text] Tc and [Formula: see text] Lu quantification parameters for a Monte Carlo modelled gamma camera
por: Di Domenico, Giovanni, et al.
Publicado: (2023)

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
por: Huang, Steve S., et al.
Publicado: (2017)

Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts
por: Goodman, Christopher D., et al.
Publicado: (2019)

Technetium Complexes and Radiopharmaceuticals with Scorpionate Ligands
por: Martini, Petra, et al.
Publicado: (2018)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
por: AlSadi, Rahaf, et al.
Publicado: (2022)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

The effect of eating on the uptake of PSMA ligands in the salivary glands
por: Mohan, V., et al.
Publicado: (2021)

Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield
por: Iudicello, Antonella, et al.
Publicado: (2022)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Missing sentinel lymph node in cutaneous melanoma
por: Dellavedova, Luca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1aalahl6rrkloker25vacj8hdo